Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics-Sexually Transmitted Disease Surveillance Network, United States, 2010-2016.
Adult
Anus Diseases
/ epidemiology
Bisexuality
/ statistics & numerical data
Condylomata Acuminata
/ epidemiology
Female
Genital Diseases, Female
/ epidemiology
Genital Diseases, Male
/ epidemiology
Heterosexuality
/ statistics & numerical data
Homosexuality, Male
/ statistics & numerical data
Humans
Male
Prevalence
Sex Factors
Sexual Partners
Sexual and Gender Minorities
/ statistics & numerical data
United States
/ epidemiology
Young Adult
Anogenital warts
genital warts
human papillomavirus (HPV)
sexually transmitted disease (STD)
sexually transmitted infection (STI)
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
16 04 2019
16 04 2019
Historique:
received:
08
08
2018
accepted:
27
11
2018
pubmed:
1
12
2018
medline:
10
1
2020
entrez:
1
12
2018
Statut:
ppublish
Résumé
Approximately 90% of genital warts are caused by human papillomavirus (HPV) types 6 and 11. In the United States, HPV vaccination has been recommended for girls and women aged ≤26 years, and since 2011, for boys and men aged ≤21 years and for gay, bisexual, and other men who have sex with men (MSM) aged ≤26 years. Data were obtained from 27 clinics participating in the STD Surveillance Network. Trends in the annual prevalence of anogenital warts (AGW) from 2010-2016 were described by sex and by the sex of sex partners. During 2010-2016, significant declines in the prevalence of AGW were observed in women aged <40 years, men who have sex with women only (MSW) aged <40 years, and MSM of all age categories. An inflection in trend in 2012 was noted for MSW aged 20-24 or 25-29 years and for MSM aged 20-24 years. The observed declines in the prevalence of AGW suggest that HPV morbidity is declining among populations attending STD clinics, including MSW, MSM, and women. Declines in younger age groups are consistent with what would be expected following the implementation of HPV vaccination. However, declines were also observed in older age groups and are not likely to be the result of vaccination.
Sections du résumé
BACKGROUND
Approximately 90% of genital warts are caused by human papillomavirus (HPV) types 6 and 11. In the United States, HPV vaccination has been recommended for girls and women aged ≤26 years, and since 2011, for boys and men aged ≤21 years and for gay, bisexual, and other men who have sex with men (MSM) aged ≤26 years.
METHODS
Data were obtained from 27 clinics participating in the STD Surveillance Network. Trends in the annual prevalence of anogenital warts (AGW) from 2010-2016 were described by sex and by the sex of sex partners.
RESULTS
During 2010-2016, significant declines in the prevalence of AGW were observed in women aged <40 years, men who have sex with women only (MSW) aged <40 years, and MSM of all age categories. An inflection in trend in 2012 was noted for MSW aged 20-24 or 25-29 years and for MSM aged 20-24 years.
CONCLUSIONS
The observed declines in the prevalence of AGW suggest that HPV morbidity is declining among populations attending STD clinics, including MSW, MSM, and women. Declines in younger age groups are consistent with what would be expected following the implementation of HPV vaccination. However, declines were also observed in older age groups and are not likely to be the result of vaccination.
Identifiants
pubmed: 30500908
pii: 5219029
doi: 10.1093/infdis/jiy684
pmc: PMC6910218
mid: NIHMS1061403
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1389-1397Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2018.
Références
J Natl Cancer Inst. 2015 Apr 29;107(6):djv086
pubmed: 25925419
Sex Transm Dis. 2014 Feb;41(2):89-93
pubmed: 24413486
MMWR Morb Mortal Wkly Rep. 2014 Jul 25;63(29):620-4
pubmed: 25055185
Sex Transm Dis. 1997 Nov;24(10):599-605
pubmed: 9383850
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24
pubmed: 17380109
Sex Transm Dis. 2013 Feb;40(2):130-5
pubmed: 23324976
N Engl J Med. 2007 May 10;356(19):1928-43
pubmed: 17494926
Sex Transm Dis. 2012 Jan;39(1):32-4
pubmed: 22183843
Proc Natl Acad Sci U S A. 1983 Jan;80(2):560-3
pubmed: 6300854
J Infect Dis. 2011 Dec 15;204(12):1886-92
pubmed: 22013227
Lancet Infect Dis. 2015 May;15(5):565-80
pubmed: 25744474
MMWR Morb Mortal Wkly Rep. 2011 Aug 26;60(33):1117-23
pubmed: 21866084
MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):626-9
pubmed: 20508593
MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60(50):1705-8
pubmed: 22189893
J Infect Dis. 2012 Sep 15;206(6):860-6
pubmed: 22815381
Am J Public Health. 2018 Jan;108(1):112-119
pubmed: 29161070
J Infect Dis. 2005 Mar 1;191(5):731-8
pubmed: 15688287
Am J Public Health. 2012 May;102(5):833-5
pubmed: 22420808
Am J Public Health. 2013 Aug;103(8):1428-35
pubmed: 23763409
J Infect Dis. 2009 Mar 15;199(6):805-14
pubmed: 19199546
Lancet Infect Dis. 2011 Jan;11(1):39-44
pubmed: 21067976
Vaccine. 2011 Jan 29;29(5):878-85
pubmed: 20971113
Sex Transm Dis. 2013 Mar;40(3):187-93
pubmed: 23403598
J Acquir Immune Defic Syndr. 2017 Jul 1;75 Suppl 3:S370-S374
pubmed: 28604441
Pediatrics. 2016 Mar;137(3):e20151968
pubmed: 26908697
MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):300-4
pubmed: 25811679
MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):630-2
pubmed: 20508594
J Clin Virol. 2005 Mar;32 Suppl 1:S16-24
pubmed: 15753008
Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):287-96
pubmed: 21300618
MMWR Morb Mortal Wkly Rep. 2017 Aug 25;66(33):874-882
pubmed: 28837546
J Acquir Immune Defic Syndr. 2012 May 1;60(1):83-90
pubmed: 22522237